naion glp-1 news Andrew Lee, MD πVision loss due to NAION
Description
Within 48 weeks of stopping, participants in the placebo group had regained an average of 6.9 percentage points of body weight
Never combine a GLP-1 RA with a DPP-4 inhibitor, no additive benefit
Novo Nordisk has also launched public education initiatives, including the Check Before You Inject campaign and the website semaglutide.com, to warn consumers about the dangers of non-FDA-approved alternatives
PMCID: PMC5890906
